Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Effect Of An Extra-Virgin Olive Oil Intake On The Delay Of Cognitive Decline: Role Of Secoiridoid Oleuropein?

Klimova B, Novotný M, Kuca K, Valis M.

Neuropsychiatr Dis Treat. 2019 Oct 29;15:3033-3040. doi: 10.2147/NDT.S218238. eCollection 2019. Review.

2.

E-learning as valuable caregivers' support for people with dementia - A systematic review.

Klimova B, Valis M, Kuca K, Masopust J.

BMC Health Serv Res. 2019 Nov 1;19(1):781. doi: 10.1186/s12913-019-4641-9.

3.

Administration of pre/probiotics with conventional drug treatment in Alzheimer's disease.

Hort J, Valis M, Angelucci F.

Neural Regen Res. 2020 Mar;15(3):448-449. doi: 10.4103/1673-5374.266057. No abstract available.

4.

The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer's Disease Patients and Its Consequence to Oxidative Stress Biomarkers.

Valis M, Herman D, Vanova N, Masopust J, Vysata O, Hort J, Pavelek Z, Klimova B, Kuca K, Misik J, Zdarova Karasova J.

Front Pharmacol. 2019 Aug 28;10:943. doi: 10.3389/fphar.2019.00943. eCollection 2019.

5.

"Muscle-Gut-Brain Axis": Can Physical Activity Help Patients with Alzheimer's Disease Due to Microbiome Modulation?

Schlegel P, Novotny M, Klimova B, Valis M.

J Alzheimers Dis. 2019;71(3):861-878. doi: 10.3233/JAD-190460.

PMID:
31476155
6.

Impact of Learning a Foreign Language on the Enhancement of Cognitive Functions Among Healthy Older Population.

Valis M, Slaninova G, Prazak P, Poulova P, Kacetl J, Klimova B.

J Psycholinguist Res. 2019 Dec;48(6):1311-1318. doi: 10.1007/s10936-019-09659-6.

PMID:
31377900
7.

Microbiome and Cognitive Impairment: Can Any Diets Influence Learning Processes in a Positive Way?

Novotný M, Klimova B, Valis M.

Front Aging Neurosci. 2019 Jun 28;11:170. doi: 10.3389/fnagi.2019.00170. eCollection 2019. Review.

8.

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators.

Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5.

PMID:
31285147
9.

MicroRNAs in Alzheimer's Disease: Diagnostic Markers or Therapeutic Agents?

Angelucci F, Cechova K, Valis M, Kuca K, Zhang B, Hort J.

Front Pharmacol. 2019 Jun 18;10:665. doi: 10.3389/fphar.2019.00665. eCollection 2019. Review.

10.

Venous Thromboembolism as an Adverse Effect During Treatment With Olanzapine: A Case Series.

Masopust J, Bazantova V, Kuca K, Klimova B, Valis M.

Front Psychiatry. 2019 May 15;10:330. doi: 10.3389/fpsyt.2019.00330. eCollection 2019.

11.

CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate.

Vališ M, Sobíšek L, Vyšata O, Klímová B, Andrýs C, Vokurková D, Masopust J, Pavelek Z.

Cells. 2019 May 15;8(5). pii: E456. doi: 10.3390/cells8050456.

12.

Vascular Cognitive Impairment: Information from Animal Models on the Pathogenic Mechanisms of Cognitive Deficits.

Hort J, Vališ M, Kuča K, Angelucci F.

Int J Mol Sci. 2019 May 15;20(10). pii: E2405. doi: 10.3390/ijms20102405. Review.

13.

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.

Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS; Evobrutinib Phase 2 Study Group.

N Engl J Med. 2019 Jun 20;380(25):2406-2417. doi: 10.1056/NEJMoa1901981. Epub 2019 May 10.

PMID:
31075187
14.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

15.

Traditional Chinese Medicine as an Effective Complementary Non-Pharmacological Approach to Mild Cognitive Impairment: A Call for Collaboration.

Klimova B, Kuca K, Valis M, Hort J.

J Alzheimers Dis. 2019;68(3):1185-1192. doi: 10.3233/JAD-181281.

PMID:
30909244
16.

N-alkylated Tacrine Derivatives as Potential Agents in Alzheimer's Disease Therapy.

Nepovimova E, Korabecny J, Hepnarova V, Jun D, Dolezal R, Muckova L, Jost P, Soukup O, Janockova J, Pham NL, Nguyen TD, Valis M, Kuca K.

Curr Alzheimer Res. 2019;16(4):333-343. doi: 10.2174/1567205016666190314163942.

PMID:
30873921
17.

Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease.

Chalupova K, Korabecny J, Bartolini M, Monti B, Lamba D, Caliandro R, Pesaresi A, Brazzolotto X, Gastellier AJ, Nachon F, Pejchal J, Jarosova M, Hepnarova V, Jun D, Hrabinova M, Dolezal R, Zdarova Karasova J, Mzik M, Kristofikova Z, Misik J, Muckova L, Jost P, Soukup O, Benkova M, Setnicka V, Habartova L, Chvojkova M, Kleteckova L, Vales K, Mezeiova E, Uliassi E, Valis M, Nepovimova E, Bolognesi ML, Kuca K.

Eur J Med Chem. 2019 Apr 15;168:491-514. doi: 10.1016/j.ejmech.2019.02.021. Epub 2019 Feb 27.

PMID:
30851693
18.

Simvastatin Inhibits Endotoxin-Induced Apoptosis in Liver and Spleen Through Up-Regulation of Survivin/NF-κB/p65 Expression.

Nežić L, Amidžić L, Škrbić R, Gajanin R, Nepovimova E, Vališ M, Kuča K, Jaćević V.

Front Pharmacol. 2019 Feb 15;10:54. doi: 10.3389/fphar.2019.00054. eCollection 2019.

19.

PPI Long Term Use: Risk of Neurological Adverse Events?

Novotny M, Klimova B, Valis M.

Front Neurol. 2019 Jan 8;9:1142. doi: 10.3389/fneur.2018.01142. eCollection 2018. Review.

20.

Encephalitis with anti-NMDA receptor antibodies: paraneoplastic or non-paraneoplastic?

Masopust J, Tvaroh A, Pavelek Z, Valis M.

Neuro Endocrinol Lett. 2018 Dec;39(5):351-354.

PMID:
30664339

Supplemental Content

Loading ...
Support Center